Athena Athena

X
[{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Supriya Lifescience

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Revive Therapeutics and Indian specialty pharma firm, Supriya Lifescience have signed an MOU to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India.

            Lead Product(s): Bucillamine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Revive Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 08, 2021

            Supriya CB

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY